Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven
New oral drugs and cheaper generics are driving interest while cost, injection aversion, uncertain long‑term effects and high payer bills are prompting cautious prescribing and tighter employer coverage.
